Influence of the Size and Charge of Carbon Quantum Dots on Their Corneal Penetration and Permeation Enhancing Properties
Source abstract
Abstract
Reaching the corneal endothelium through the topical administration of therapeutic drugs remains a challenge in ophthalmology. Besides, endothelial cells are not able to regenerate, and diseases at this site can lead to corneal blindness. Targeting the corneal endothelium implies efficient penetration through the three corneal layers, which still remains difficult for small molecules. Carbon quantum dots (CQDs) have demonstrated great potential for ocular nanomedicine. This study focuses on the corneal penetration abilities of differently charged CQDs and their use as permeation enhancers for drugs. Excised whole bovine eyes were used as an ex vivo model to investigate corneal penetration of CQDs derived from glucosamine using β-alanine, ethylenediamine, or spermidine as a passivation agent. It was found that negatively charged CQDs have limited corneal penetration ability, while positively charged CQDs derived from glucosamine hydrochloride and spermidine (CQD-S) penetrate the entire corneal epithelium all the way down to the endothelium. CQD-S were shown to enhance the penetration of FITC-dextran 150 kDa, suggesting that they could be used as efficient penetration enhancers for therapeutic delivery to the corneal endothelium.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Corneal Surgery and Treatments · Ocular Surface and Contact Lens · Corneal surgery and disorders
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Univ. Lille, CNRS, Centrale Lille, Univ. Polytechnique Hauts-de-France, UMR 8520 - IEMN, F-59000 Lille, France
Laboratory of General Biochemistry and Physical Pharmacy, Faculty of Pharmaceutical Sciences, Ghent University, 9000 Ghent, Belgium
Funding
Programme Investissement d?Avenir · Marie Sklodowska-Curie grant
References (31)
Show source-provided references
1. 10.1016/j.jconrel.2021.04.00810.1016/j.jconrel.2021.04.008 ↗
2. WHO, Universal eye health: a global action plan 2014-2019. https://www.vision2020australia.org.au/resources/universal-eye-health-a-global-action-plan-2014-2019/ 2013, accessed 30 August 2022.
3. 10.1016/j.addr.2018.03.00910.1016/j.addr.2018.03.009 ↗
4. 10.3928/1081597X-20090813-0410.3928/1081597X-20090813-04 ↗
5. Knupp C. · 2009 · 78 · 2510.1016/S1876-1623(08)78002-7 ↗
6. 10.1167/iovs.08-263410.1167/iovs.08-2634 ↗
7. 10.1016/j.survophthal.2017.07.00410.1016/j.survophthal.2017.07.004 ↗
8. 10.1038/s41598-018-22821-910.1038/s41598-018-22821-9 ↗
9. 10.1097/ICO.000000000000210910.1097/ICO.0000000000002109 ↗
10. 10.1016/j.exer.2005.06.01210.1016/j.exer.2005.06.012 ↗
11. 10.1136/bjophthalmol-2020-31614910.1136/bjophthalmol-2020-316149 ↗
12. 10.1001/jamaophthalmol.2015.477610.1001/jamaophthalmol.2015.4776 ↗
13. 10.1167/iovs.15-1759510.1167/iovs.15-17595 ↗
14. 10.1016/j.ejpb.2015.02.01910.1016/j.ejpb.2015.02.019 ↗
15. 10.1007/s13346-016-0339-210.1007/s13346-016-0339-2 ↗
16. 10.1021/js980259410.1021/js9802594 ↗
17. 10.1039/D1NH00157D10.1039/D1NH00157D ↗
18. 10.1021/acsnano.7b0102310.1021/acsnano.7b01023 ↗
19. 10.3390/pharmaceutics1109046010.3390/pharmaceutics11090460 ↗
20. 10.1039/C9NR00376B10.1039/C9NR00376B ↗
21. 10.1371/journal.pone.013202310.1371/journal.pone.0132023 ↗
22. 10.2147/IJN.S17319810.2147/IJN.S173198 ↗
23. 10.1155/2013/23835110.1155/2013/238351 ↗
24. 10.1016/j.exer.2019.10769710.1016/j.exer.2019.107697 ↗
25. 10.1016/j.preteyeres.2015.07.00210.1016/j.preteyeres.2015.07.002 ↗
26. 10.1039/C8CS00445E10.1039/C8CS00445E ↗
27. 10.2147/IJN.S25479210.2147/IJN.S254792 ↗
28. 10.2147/IJN.S9034710.2147/IJN.S90347 ↗
29. 10.1007/s13346-018-0546-010.1007/s13346-018-0546-0 ↗
30. 10.1016/0378-5173(92)90308-O10.1016/0378-5173(92)90308-O ↗
31. 10.1016/j.jconrel.2022.08.00910.1016/j.jconrel.2022.08.009 ↗